Medicenna Therapeutics Corp.
MDNAF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MDNAF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDNAF
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. As of March 31, 2023, the company reported cash and equivalents of $33.6 million and a net loss of $10.0 million for the period.
Key risk: No approved products or revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2023.
Tracking 1 clinical trial for Medicenna Therapeutics Corp..
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. As of March 31, 2023, the company reported cash and equivalents of $33.6 million and a net loss of $10.0 million for the period.
- Cash and equivalents of $33.6 million as of 2023-03-31 [sec].
- Net income of -$10.0 million for the period ended 2023-03-31 [sec].
- Shareholders' equity of $38.1 million as of 2023-03-31 [sec].
- The company operates in a competitive landscape with numerous competitors conducting trials for advanced solid tumors, including KRAS G12D mutations and other targets [competitor_trial].
What works
- Cash position of $33.6 million as of 2023-03-31 provides a runway for ongoing operations [sec].
- Shareholders' equity of $38.1 million indicates a solid equity base relative to liabilities [sec].
What to weigh
- Net loss of $10.0 million for the period ended 2023-03-31 reflects ongoing operational expenses without corresponding revenue [sec].
- The company faces intense competition from multiple entities developing therapies for advanced solid tumors, including those targeting KRAS mutations [competitor_trial].
Risks & what to watch (2)›
Key risks
- No approved products or revenue — The company has no approved products and reported a net loss of $10.0M as of 2023-03-31, indicating no revenue from product sales [sec].
- Intense competitive landscape — Multiple competitors are conducting trials for advanced solid tumors, including KRAS G12D inhibitors, which may limit market opportunity [competitor_trial].
What to watch
- Clinical trial progress and data readouts for the company's lead candidates.
- Updates on cash runway and any new financing activities.
- Competitive developments in the KRAS G12D and solid tumor immunotherapy space.
Sources: Competitor trials · Generated August 29, 2026 · How we verify sources →
Run Medicenna Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Medicenna Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.2 months
D/E 0.24
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
1
Total value held
$200K
| Holder | Shares | Value |
|---|---|---|
| org partners llc | 175,000 | $200K |
Short Interest
as of Apr 30, 2026- % of float
- 0.7%
- Days to cover
- 0.8
- Shares short
- 109,389
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDNAF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Medicenna Therapeutics Corp.?
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. As of March 31, 2023, the company reported cash and equivalents of $33.6 million and a net loss of $10.0 million for the period.
Who is the CEO of Medicenna Therapeutics Corp.?
Dr. Fahar Merchant Ph.D. is the chief executive officer of Medicenna Therapeutics Corp. (MDNAF).
Where is Medicenna Therapeutics Corp. headquartered?
Medicenna Therapeutics Corp. (MDNAF) is headquartered in Toronto, ON, Canada.
What therapeutic areas does Medicenna Therapeutics Corp. focus on?
Medicenna Therapeutics Corp. develops therapies across Oncology, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.